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The SARS- CoV-2 pandemic and covid-19 
diffusion are an international public health 
emergency.1 Cancer patients are particularly 
exposed to infections and their potential 
complications.2 In this context, the usual 
clinical decision- making process in radiation 
therapy is being consistently revised.3 There 
is an urgent need to share expertise and offer 
emergency guidance. It is crucial to mini-
mise contacts and to reduce the complexity 
of radiation treatments where possible to 
optimise the workforce, keeping intact the 
effectiveness of the interventions.4 Radiation 
and systemic therapy modifications should 
be implemented depending on local circum-
stances.5 A general guiding principle should 
include approaches where clinical equiva-
lence supported by trials testing de- escalation 
strategies is present even without level 1–2 
evidence (box 1, bullet points 1).3 Patients 
with cancer have an intrinsic degree of frailty 
and therefore are prone to covid-19 compli-
cations. Age and comorbidities have been 
reported as independent risk factors for poor 
outcome during covid-19 infection and, of 
note, more than half of cancer patients are 
elderly and have significant comorbidities 
(box 1, bullet points 2).6 Hence, an appro-
priate evaluation of the risk- benefit of radi-
ation therapy treatments is cogent. Urgent 
cases and non- deferrable treatments (ie, 
active tumours, spinal cord compression, life 
threatening bleeding) should be initiated or 
continued, provided there is full compliance 
with the safety regulations of local authorities 
for both patients and staff members. In non- 
urgent cases, irradiation can be postponed to 
an extent, depending on the clinical setting 
and the possibility to offer patients bridging 
systemic therapies. Whenever radiation 
therapy is indicated, dose prescription, frac-
tionation and delivery techniques should be 
adapted, reduced in duration, and optimised 
(box 1, bullet points 3 and 4).
A timely example of precision medicine 
application is non- metastatic breast cancer 
radiation therapy, favouring moderate 
hypofractionation, partial breast irradiation, 
schedule optimisation, and tumour bed boost 
omission in adequately selected patients.7 8 
Indeed, a practical international guideline to 
be used during the covid-19 pandemic has 
been implemented in several European coun-
tries.5 Although lung cancer patients usually 
present with respiratory symptoms (ie, cough, 
dyspnoea), they do not seem to have a higher 
mortality risk compared with other cancer 
types.2 Especially in areas where the epidemic 
is rapidly rising, surgeons are forced to face 
a reduction in activity and are referring a 
higher number of operable early stage lung 
cancer patients to stereotactic body radiation 
therapy (SBRT).9 Sequential regimens should 
be preferred in patients suitable for concur-
rent chemo- radiation, while no data have 
been reported on immunotherapy; therefore, 
a case- by- case analysis of the risk- benefit ratio 
is advised. Regarding patients with low- grade 
gliomas and meningiomas, radiation therapy 
should be postponed or even omitted in the 
postoperative setting. Patients with high- 
grade gliomas with significant neurological 
deficit need to be reviewed on a case- by- case 
basis in order to assess the appropriateness 
of surgery. Irradiation might be omitted in 
methylated glioblastoma patients aged >60 
years.10 In any case, moderate and/or ultra- 
hypofractionated regimens should be consid-
ered whenever possible.2 8–10
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Box 1 Summary of cancer care contexts and practical 
recommendations for radiation therapy during the covid-19 
outbreak
Bullet point 1: Global scenario
 ► The covid-19 pandemic is an international public health emergency.
 ► Cancer patients are frail and particularly prone to developing severe 
events related to covid-19.
 ► The clinical decision- making process for radiation therapy should be 
revised in this situation.
Bullet point 2: Covid-19 and cancer patients
 ► Cancer patients are more likely to be old and have comorbidities.
 ► Covid-19 is more severe in elderly patients and in those with 
comorbidities.
 ► Reducing the frequency of hospital visits and proper isolation pro-
tocols are warranted.
Bullet point 3: Radiation therapy during the covid-19 
pandemic
 ► A careful evaluation of the risk- benefit ratio for each treatment 
should be performed for every patient.
 ► Urgent and non- deferrable cases should be safely planned for treat-
ment; all the other treatments should be deferred.
 ► Radiation dose prescription, fractionation and technique should be 
optimised and adapted to the emergency context.
Bullet point 4: Specific clinical indications for radiation 
therapy
 ► To adopt treatments following the principle of clinical equivalence 
supported by trials which tested de- escalation strategies even with-
out level 1–2 evidence.
 ► To favour reduction and simplification of radiation therapy duration 
(ie, hypofractionation, stereotactic body radiation therapy).
 ► To favour precision medicine and de- escalation approaches follow-
ing a case- by- case assessment.
Bullet point 5: Deciding to treat with radiotherapy a cancer 
patient with covid-19
 ► If a patient is upfront positive, consider tumour biology, burden of 
symptoms and toxicity profile.
 ► If a patient turns positive, balance the risk between cancer progres-
sion and severe covid-19.
 ► Consider that ‘less might be better’ in this scenario.
Bullet point 6: Patient safety
 ► Follow WHO indications and national/international societies’ 
recommendations.
 ► Limit access to radiation department, implement ‘triage’, respect 
social distancing, institute sanitisation.
 ► Prepare patient and caregivers, communicate and share informa-
tion, operate thoughtfully.
Bullet point 7: Staff safety
 ► Staff training and education is crucial.
 ► A covid-19 dedicated staff is advisable (if feasible).
 ► Personal protection equipment is mandatory.
Bullet point 8: Technology facilitation
 ► Artificial intelligence- based imaging analysis allows reliable diagno-
sis for covid-19 pneumonia.
 ► The epidemic has boosted the use of video and teleconsultation, 
ensuring cancer care continuity.
Continued
The decision to start treatment for a covid-19 patient 
should be based on the biological features of the tumour, 
the symptom burden of the patient and the safety profile 
of the treatment. If a patient gets infected during the 
treatment the decision to proceed with it should be based 
on the balance between the risk of cancer progression 
versus the probability of suffering from severe covid-19 
syndrome (box 1, bullet points 5).
Particular attention should be paid to patient safety. 
Most of the available indications come from the WHO, 
national authorities, and radiation therapy and oncology 
societies.11 12 They include an accurate triage to iden-
tify positive or suspected cases; the limited access to the 
radiotherapy department; paying careful attention to 
respect social distancing; and the availability of sanitising 
devices and personal protection equipment (PPE) (box 
1, bullet points 6).13 All radiation oncology professionals 
(including physicians, therapists, medical physicists 
and nurses) must be properly trained and periodically 
updated about the clinical characteristics of covid-19, the 
risks of professional exposure, the correct use of PPE, and 
the available prevention and protection measures.
It is advisable to minimise the number of operators 
exposed to covid-19 positive or suspect patients. There-
fore, depending on the available human resources, the 
staff might be divided into distinct units, specifically in 
charge of covid-19 positive cases.
In order to preserve their health and avoid virus trans-
mission, healthcare professionals closely involved in the 
management of covid-19 positive or suspect patients 
must properly use PPE, including respiratory protec-
tion devices (preferably FFP2 or FFP3 respirators), eye 
protection goggles, surgical caps, long- sleeved water- 
resistant gowns, double gloves and shoe covers. Suspect 
infections or onset of symptoms attributable to covid-19 
must be promptly notified, reporting and informing all 
the personnel and/or patients that had direct contacts. 
Isolation of suspected cases is mandatory, and the execu-
tion of repeated nasopharyngeal diagnostic swabbing 
is needed (box 1, bullet points 7). Hospital meetings, 
tumour boards and case discussions should be performed 
remotely. In this sense, the massive use of technology 
and artificial intelligence (AI) approaches is providing 
innovative tools, especially for new diagnostic and moni-
toring solutions for clinicians facing the epidemic in daily 
activity. Promising results have been obtained from AI 
applications for CT imaging- based diagnosis, and several 
e- health applications (eg, multidimensional data collec-
tion apps, video consultation platforms, virtual meeting 
tools) are spreading to ensure cancer care continuity, 
avoiding unnecessary physical contacts between patients 
and healthcare professionals and other hospital personnel 
(box 1, bullet points 8).14
As young oncologists working in several different frame-
works, we are all implementing these recommendations 
in order to keep cancer care as safe as possible for both 
patients and healthcare providers (box 1). Depending 
on specific directives of the single institutions, in order 
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Box 1 Continued
 ► Health informatics offers new tools for patient monitoring and may 
help in reducing the spread of covid-19.
to warrant ethical and effective treatments, a high level 
of homogeneity of protection against covid-19 strate-
gies should be harmoniously implemented across Italian 
oncology centres. As recently suggested,15 we fully endorse 
the young oncologist perspectives (YOP) suggesting the 
need to protect Yourself and your family (both at work 
and in personal life), provide Oncological care of our 
patients (by trying to minimise the impact of this emer-
gency situation on the usual care), and prevent Patients 
from being infected. These same considerations should 
be fully applied in the field of radiation oncology.
Author affiliations
1Department of Experimental and Clinical Biomedical Sciences "M. Serio", 
University of Florence, Firenze, Italy
2Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria 
Careggi, Firenze, Italy
3Department of Oncology, Radiation Oncology, University of Turin, Torino, Italy
4Health Science Department (DISSAL), University of Genoa, Genova, Italy
5Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, 
Italy
6Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Roma, Italy
7Department of Radiation Oncology, Institut d'Oncologie Thoracique (IOT), Villejuif, 
France
8Radiotherapy Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
9Division of Radiation Oncology, IEO - European Institute of Oncology, IRCCS, Milan, 
Italy
10Department of Oncology and Hemato- Oncology, University of Milan, Milan, Italy
11Radiation Oncology Unit, Santa Maria della Misericordia Hospital, Rovigo, Italy
12Radiation Oncology Unit - Department of Biomedical, Dental Science, and 
Morphological and Funcitional Images, University of Messina, Messina, Italy
13Department of Radiation Oncology, University of Brescia and Spedali Civili 
Hospital, Brescia, Italy
14Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS 
Ospedale Policlinico San Martino, Genova, Italy
15Department of Internal Medicine and Medical Specialties (DiMI), School of 
Medicine, University of Genoa, Genova, Italy
Twitter Icro Meattini @Icro_Meattini and Matteo Lambertini @matteolambe
Contributors All authors equally contributed.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, any changes made are indicated, and the use is non- commercial. 
See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Icro Meattini http:// orcid. org/ 0000- 0002- 1861- 2895
Matteo Lambertini http:// orcid. org/ 0000- 0003- 1797- 5296
RefeRences
 1 Guan W- jie, Ni Z- yi, Hu Y, et al. Clinical characteristics of coronavirus 
disease 2019 in China. N Engl J Med Overseas Ed. In Press 2020.
 2 Liang W, Guan W, Chen R, et al. Cancer patients in SARS- 
CoV-2 infection: a nationwide analysis in China. Lancet Oncol 
2020;21:335–7.
 3 Simcock R, Thomas TV, Estes C, et al. COVID-10: Global Radiation 
Oncology’s targeted response for pandemic preparedness. Clin 
Transl Oncol. In Press 2020.
 4 Filippi AR, Russi E, Magrini SM, et al. COVID-19 outbreak in northern 
Italy: first practical indications for radiotherapy departments. 
Int J Radiat Oncol Biol Phys. In Press 2020. doi:10.1016/j.
ijrobp.2020.03.007. [Epub ahead of print: 18 Mar 2020].
 5 Coles CE, Aristei C, Bliss J, et al. International guidelines on radiation 
therapy for breast cancer during the COVID-19 pandemic. Clin Oncol 
2020;32:279–81.
 6 Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized 
patients with 2019 novel coronavirus- infected pneumonia in Wuhan, 
China. JAMA 2020. doi:10.1001/jama.2020.1585. [Epub ahead of 
print: 07 Feb 2020].
 7 Brunt AM, Haviland J, Sydenham M, et al. OC-0595: FAST- Forward 
phase 3 RCT of 1- week hypofractionated breast radiotherapy:3- year 
normal tissue effects. Radiother Oncol 2018;127:S311–2.
 8 Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast 
irradiation using intensity- modulated radiotherapy versus whole 
breast irradiation: 5- year survival analysis of a phase 3 randomised 
controlled trial. Eur J Cancer 2015;51:451–63.
 9 Videtic GM, Hu C, Singh AK, et al. Schedules for medically 
inoperable patients with stage I peripheral non- small cell lung 
cancer: NRG oncology RTOG 0915 (NCCTG N0927). Int J Radiat 
Oncol Biol Phys 2015;93:757–64.
 10 Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus 
standard 6- week radiotherapy versus hypofractionated radiotherapy 
in patients older than 60 years with glioblastoma: the Nordic 
randomised, phase 3 trial. Lancet Oncol 2012;13:916–26.
 11 Rischio infettivo da Coronavirus COVID 19: indicazioni per 
l’Oncologia da parte del Presidente AIOM, del Presidente eletto 
AIOM, del Presidente CIPOMO e del Presidente COMU. Available: 
https://www. aiom. it/ wp- content/ uploads/ 2020/ 03/ 20200313_ COVID- 
19_ indicazioni_ AIOM- CIPOMO- COMU. pdf
 12 Associazione Italiana di Radioterapia e Oncologia Clinica (AIRO). 
Documento di indirizzo per La valutazione E La gestione del rischio 
dei Pazienti E degli operatori Nei reparti di radioterapia oncologica 
in corso di diffusione del COVID-19. Available: https://www. 
radioterapiaitalia. it/ evento/ emergenza- covid- 19
 13 Krengli M, Ferrara E, Mastroleo F, et al. Running a radiation oncology 
department at the time of coronavirus: an Italian experience. Adv 
Radiat Oncol 2020.
 14 Reeves JJ, Hollandsworth HM, Torriani FJ, et al. Rapid response 
to COVID-19: health informatics support for outbreak management 
in an academic health system. J Am Med Inform Assoc 2020:pii: 
ocaa037.
 15 Lambertini M, Toss A, Passaro A, et al. Cancer care during the 
spread of coronavirus disease 2019 (COVID-19) in Italy: young 
oncologists' perspective. ESMO Open 2020;5:e000759.
 o
n
 July 8, 2020 by guest. Protected by copyright.
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2020-000779 on 15 April 2020. Downloaded from
 
